Treatments & Services

Available Cancer & Hematology Research Trials

Throughout the last century the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads. You do not have to leave the area to receive premier cancer care.

If you are interested in learning more about our research program, please call the VOA Research Department in the area closest to you:

Peninsula: (757) 873-9400

  • Hampton
  • Newport News
  • Williamsburg

Southside: (757) 466-8683

  • Norfolk
  • Virginia Beach


Breast Cancer Research

  • USO 17082

    USO 17082: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (I3Y-MC-JPCF) monarchE

    Available at 3 locations

  • USO 16224

    USO 16224 A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with Advanced Triple Negative Breast Cancer, with a Phase 1b Lead in Phase (SNDX-275-0602)

    Available at 5 locations

  • USO 17027

    A Multi-Centre, Open-Label, Randomized Clinical Trial Comparing The Efficacy And Safety Of The Antibody-Drug Conjugate SYD985 To Physician's Choice In Patients With HER2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer

    Available at 1 location

  • USO 16023

    An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

    Available at 5 locations

  • USO 17009

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

    Available at 5 locations

  • Alliance A011502 (ABC Trial)

    A Randomized Phase III Double Blinded Placebo-Controlled Trial Of Aspirin As Adjuvant Therapy For Node-Positive, HER2 Negative Breast Cancer

    Available at 6 locations

  • Novartis CLEE011A2404 (CompLEEment)

    CompLEEment: An Open-Label, Multicenter, Phase IIIB Study To Assess The Safety And Efficacy Of Ribociclib (LEE011) In Combination With Letrozole For The Treatment Of Men And Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer (ABC) With No Prior Hormonal Therapy For Advanced Disease

    Available at 4 locations

  • USO 16208

    USO 16208: A Phase III Randomized, Double-Blind Study To Evaluate Pembrolizumab Plus Chemotherapy Vs Placebo Plus Chemotherapy As Neoadjuvant Therapy And Pembrolizumab Vs Placebo As Adjuvant Therapy For Triple Negative Breast Cancer (TNBC) MK-3475-522

    Available at 3 locations

  • INO-VT-464-CL-006

    A Phase 1/2 Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy Of VT-464 In Patients With Advanced Breast Cancer

    Available at 2 locations

  • HCRN BRE12-158

    A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer

    Available at 6 locations

Gastrointestinal Cancer Research

  • USO 16164

    A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649) CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649)

    Available at 5 locations

Genitourinary Cancer Research

  • USO 15247

    USO 15247: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD)

    Available at 5 locations

  • USO 17165

    USO 17165: Phase 1b/2 Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations (42756493BLC2002)

    Available at 1 location

  • USO 17146

    USO 17146: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (1205-201)

    Available at 1 location

  • Duke Panther Pro00075097

    Duke Panther Pro00075097: Prospective Study of Apalutamide and Abiraterone Acetate In Chemo Therapy Naïve Men with mCRPC Stratified by Race (Pro00075097)

    Available at 2 locations

  • USO 16237

    A Multicenter, Open-Label Phase 2 Study Of Rucaparib In Patients With Metastatic Castration-Resistant Prostate Cancer Associated With Homologous Recombination Deficiency TRITON2: CO-338-052

    Available at 2 locations

  • USO 17005

    A Single-Arm, Open-Label, Multicenter Study Of Enfortumab Vedotin (ASG-22CE) For Treatment Of Patients With Locally Advanced Or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy - SGN22E-001

    Available at 5 locations

  • HCRN GU14-188

    HCRN GU14-188: Phase Ib/Ii Study Of Neoadjuvant Pembrolizumab (Mk-3475) With Gemcitabine-Cisplatin (Cisplatin Eligible) Or Gemcitabine (Cisplatin-Ineligible) In Subjects With T2-4an0m0 Urothelial Cancer

    Available at 5 locations

  • MDV3800-06

    A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)

    Available at 2 locations

  • USO 16251

    A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

    Available at 2 locations

  • USO 16160

    USO 16160: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative To Placebo Plus Abiraterone Plus Prednisone/Prednisolone In Patients With Asymptomatic Or Mildly Symptomatic Metastatic Castrate-Resistant Prostate Cancer With PTEN-Loss (PTEN Diagnostic Positive) Tumors - Roche Co39303

    Available at 5 locations

  • PCCTC c12-108

    An Exploratory Randomized Phase 2 Multicenter Trial Of Abiraterone Acetate With Or Without Cabazitaxel In Treatment Of Metastatic Castration Resistant Prostate Cancer

    Available at 1 location

  • USO 16130

    A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

    Available at 5 locations

  • USO 12177

    A Phase III Double-­‐blinded,Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer (2012-PT023)

    Available at 5 locations

  • HCRN GU14-182

    A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

    Available at 5 locations

  • HCRN 14-188

    A Phase Ib/II Study Of Neoadjuvant Pembrolizumab (MK-3475) With Gemcitabine-Cisplatin (Cisplatin Eligible) Or Gemcitabine (Cisplatin-Ineligible) In Patients with T2-4aN0M0 Urothelial Cancer

    Available at 4 locations

GYN Cancer Research

  • USO 16233

    A Phase III, Multicenter, Randomized, Study Of Atezolizumab Versus Placebo Administered In Combination With Paclitaxel, Carboplatin, And Bevacizumab To Patients With Newly-Diagnosed Stage Iii Or Stage Iv Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer - Yo39523

    Available at 3 locations

Head & Neck Cancer Research

  • RTOG 1216

    RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

    Available at 5 locations

Leukemia & Lymphoma Research

  • USO 13064

    A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

    Available at 5 locations

Solid Tumors Research

  • USO 18020

    USO 18020: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

    Available at 1 location

  • Ignyta (RXDX 101-02)

    An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    Available at 1 location

  • USO 15226

    A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101)

    Available at 1 location

  • USO 15239

    A Phase I, Open-Label, Multiple-Ascending Dose Trial To Investigate The Safety, Tolerability, Pharmacokinetics, Biological And Clinical Activity Of MSB0011359C In Subjects With Metastatic Or Locally Advanced Solid Tumors And Expansion To Selected Indications

    Available at 1 location